IL17A and psoriasis: Recently, interleukin (IL)‐17 and IL‐23 inhibitors have enabled the achievement of previously inconceivable outcomes such as the Psoriasis Area Severity Index (PASI) 90, and 100, and an important impact on quality of life such as the Dermatology Life Quality Index (DLQI) 0/1.3